Teva's Qnaze meets endpoints in phase-3 trial

JERUSALEM — An investigational drug made by Teva Pharmaceutical Industries for treating allergies is safe and effective, according to results of a late-stage clinical trial announced Wednesday.

Teva said the phase-3 trial of the nasally inhaled drug Qnaze (beclomethasone dipropionate) showed that it significantly relieved symptoms of seasonal and perennial allergic rhinitis compared with placebo while demonstrating a similar safety profile.

Teva reported results from a phase-3 trial of the drug in patients with seasonal allergies at the American Coolege of Allergy, Asthma and Immunology’s annual meeting last year.